Lymphoma Treatment Market
Lymphoma Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation, CAR-T Cell Therapy), By Lymphoma Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Route of Administration (Intravenous (IV), Oral, Subcutaneous), By Therapy Line (First-Line Therapy, Second-Line Therapy, Third-Line & Salvage Therapy), By End-User (Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Research Institutes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Technology Platform (Cell Therapy, Biologics, Small Molecule Drugs, Gene Therapy), Forecast Period (2026-2035)
Industry Overview
Lymphoma treatment market size was valued at $28 billion in 2025 and is projected to reach $63 billion by 2035, growing at a CAGR of 8.50% between 2026 and 2035. The market includes therapies designed to treat lymphoma, a group of blood cancers affecting the lymphatic system, using chemotherapy, immunotherapy, targeted therapy, and advanced cell-based treatments. A key driver supporting market growth is the increasing global cancer burden and rising demand for advanced oncology therapies. According to the World Health Organisation, cancer caused approximately 10 million deaths globally in 2022, indicating a growing need for effective treatment solutions. Additionally, the International Agency for Research on Cancer estimates that global cancer cases will reach over 35 million by 2050, significantly increasing demand for lymphoma therapies. The expansion of biologics, CAR-T therapies, and precision medicine approaches is transforming treatment outcomes. Increasing healthcare investments, rising awareness, and improved diagnostic capabilities are further accelerating adoption across hospitals and speciality cancer centres.
Market Dynamics
Rising Cancer Burden and Oncology Innovation Driving Market Growth
The increasing incidence of lymphoma and other cancers is a major driver of the Lymphoma Treatment market. According to the World Health Organisation, cancer cases are projected to rise significantly over the coming decades, driving demand for advanced oncology treatments. Lymphoma, particularly non-Hodgkin lymphoma, represents a substantial portion of hematologic malignancies worldwide. The European Federation of Pharmaceutical Industries and Associations highlights that oncology accounts for more than 40% of pharmaceutical R&D pipelines, indicating a strong industry focus on cancer therapies. Companies such as Roche Holding AG and Novartis AG are investing in advanced immunotherapies and CAR-T technologies to enhance treatment outcomes. Between 2025 and 2026, pharmaceutical companies are focusing on combination therapies, biologics, and gene-based treatments, further accelerating innovation and market expansion.
High Treatment Costs and Complex Manufacturing Limiting Market Growth
Despite strong growth prospects, the Lymphoma Treatment market faces challenges related to high treatment costs and complex therapy development. Advanced therapies such as CAR-T involve high production costs, specialised infrastructure, and complex regulatory approvals, limiting accessibility in emerging markets. According to the International Federation of Pharmaceutical Manufacturers & Associations, biologics and cell-based therapies require highly sophisticated manufacturing processes, increasing overall treatment costs and supply chain complexity. Additionally, differences in regulatory frameworks across countries create barriers to global expansion. Companies are addressing these challenges by investing in scalable manufacturing, automation, and partnerships to improve efficiency. The development of off-the-shelf therapies and biosimilars is also expected to reduce costs and enhance accessibility over time.
Market Segmentation
- Based on the Treatment Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation, and CAR-T Cell Therapy.
- Based on the Lymphoma Type, the market is segmented into Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
- Based on the Route of Administration, the market is segmented into Intravenous (IV), Oral, and Subcutaneous.
- Based on the Therapy Line, the market is segmented into First-Line Therapy, Second-Line Therapy, and Third-Line & Salvage Therapy.
- Based on the End-User, the market is segmented into Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, and Research Institutes.
- Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
- Based on the Technology Platform, the market is segmented into Cell Therapy, Biologics, Small Molecule Drugs, and Gene Therapy.
Immunotherapy Segment Leads the Market
The immunotherapy segment dominates the Lymphoma Treatment market due to its targeted mechanism of action and improved patient survival outcomes. These therapies enhance immune system responses against cancer cells, offering better efficacy compared to traditional chemotherapy. Companies such as Bristol Myers Squibb and Roche Holding AG have expanded their immunotherapy pipelines between 2022 and 2026, focusing on combination treatments and next-generation biologics. Increasing clinical success rates and growing physician preference for less toxic therapies are further strengthening the dominance of this segment.
CAR-T Cell Therapy Segment to Record Strong Growth
The CAR-T cell therapy segment is expected to witness the fastest growth during the forecast period. These therapies offer personalised treatment options and have demonstrated strong efficacy in relapsed and refractory lymphoma cases. Companies such as Kite Pharma, Inc. and Novartis AG are investing in expanding manufacturing capacity and clinical pipelines. Increasing regulatory approvals, technological advancements, and rising adoption of precision medicine are further driving growth in this segment.
Regional Outlook
The global Lymphoma Treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the market due to its advanced healthcare infrastructure and strong oncology research capabilities. According to the U.S. Food and Drug Administration, multiple CAR-T therapies have been approved for lymphoma treatment, accelerating the adoption of advanced therapies. High healthcare expenditure and the presence of major pharmaceutical companies further strengthen market leadership.
China to Record Strong Growth
China is expected to witness strong growth due to increasing cancer incidence and expanding healthcare infrastructure. According to the International Trade Centre, pharmaceutical production and trade have increased significantly, supporting the availability of oncology drugs. Government initiatives and rising healthcare investments are further driving demand for lymphoma treatments.
Competitive Landscape
The global Lymphoma Treatment market is highly competitive, with major players focusing on product innovation, clinical development, and strategic collaborations. Leading companies such as Roche Holding AG, Novartis AG, Bristol Myers Squibb, Kite Pharma, Inc., and AbbVie Inc. dominate the market through strong oncology portfolios and continuous investment in advanced therapies, including biologics, CAR-T, and targeted treatments. Companies are also expanding manufacturing capabilities and entering partnerships to strengthen their global presence and improve treatment accessibility.
Recent Developments
- In March 2026, Bristol Myers Squibb transformed the classical Hodgkin lymphoma treatment paradigm with expanded the U.S. and EMA approvals for OPDIVO® (nivolumab).
- In December 2025, Roche’s Columvi combination shows sustained survival benefit at three-year follow-up of the pivotal phase III STARGLO study.
- In May 2025, AbbVie presented new clinical data at ASCO 2025 across a range of difficult-to-treat solid tumours and blood cancers, showcasing the breadth and depth of its oncology portfolio. The findings highlight the company’s continued focus on advancing innovative therapies and strengthening its pipeline.
- In January 2024, Kite received U.S. FDA approval for a manufacturing process change for Yes carta® CAR-T therapy. This reduces the median turnaround time from leukapheresis to product release from 16 days to 14 days. The improvement enhances treatment speed and supports better outcomes for lymphoma patients requiring timely therapy.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualised market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Lymphoma Treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Lymphoma Treatment Market Sales Analysis – Treatment Type | Lymphoma Type | Route of Administration | Therapy Line | End-User | Distribution Channel | Technology Platform ($ Million)
- Lymphoma Treatment Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Lymphoma Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Lymphoma Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Lymphoma Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Lymphoma Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Lymphoma Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Lymphoma Treatment Market Revenue and Share by Manufacturers
- Lymphoma Treatment Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Roche Holding AG
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Novartis AG
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Bristol Myers Squibb
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Kite Pharma, Inc.
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 AbbVie Inc.
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Lymphoma Treatment Market Sales Analysis by Treatment Type ($ Million)
5.1 Chemotherapy
5.2 Immunotherapy
5.3 Targeted Therapy
5.4 Radiation Therapy
5.5 Stem Cell Transplantation
5.6 CAR-T Cell Therapy
- Global Lymphoma Treatment Market Sales Analysis by Lymphoma Type ($ Million)
6.1 Hodgkin Lymphoma
6.2 Non-Hodgkin Lymphoma
- Global Lymphoma Treatment Market Sales Analysis by Route of Administration ($ Million)
7.1 Intravenous (IV)
7.2 Oral
7.3 Subcutaneous
- Global Lymphoma Treatment Market Sales Analysis by Therapy Line ($ Million)
8.1 First-Line Therapy
8.2 Second-Line Therapy
8.3 Third-Line & Salvage Therapy
- Global Lymphoma Treatment Market Sales Analysis by End-User ($ Million)
9.1 Hospitals
9.2 Speciality Cancer Centres
9.3 Ambulatory Surgical Centres
9.4 Research Institutes
- Global Lymphoma Treatment Market Sales Analysis by Distribution Channel ($ Million)
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Online Pharmacies
- Global Lymphoma Treatment Market Sales Analysis by Technology Platform ($ Million)
11.1 Cell Therapy
11.2 Biologics
11.3 Small Molecule Drugs
11.4 Gene Therapy
- Regional Analysis (Right-Aligned Numbering)
12.1 North American Lymphoma Treatment Market Sales Analysis – Treatment Type | Lymphoma Type | Route of Administration | Therapy Line | End-User | Distribution Channel | Technology Platform Country ($ Million)
12.1.1 United States
12.1.2 Canada
12.2 European Lymphoma Treatment Market Sales Analysis – Treatment Type | Lymphoma Type | Route of Administration | Therapy Line | End-User | Distribution Channel | Technology Platform | Country ($ Million)
12.2.1 UK
12.2.2 Germany
12.2.3 Italy
12.2.4 Spain
12.2.5 France
12.2.7 Rest of Europe
12.3 Asia-Pacific Lymphoma Treatment Market Sales Analysis – Treatment Type | Lymphoma Type | Route of Administration | Therapy Line | End-User | Distribution Channel | Technology Platform | Country ($ Million)
12.3.1 China
12.3.2 Japan
12.3.3 South Korea
12.3.4 India
12.3.5 Australia & New Zealand
12.3.6 ASEAN Countries
12.3.7 Rest of Asia-Pacific
12.4 Rest of the World Lymphoma Treatment Market Sales Analysis – Treatment Type | Lymphoma Type | Route of Administration | Therapy Line | End-User | Distribution Channel | Technology Platform | Country ($ Million)
12.4.1 Latin America
12.4.2 Middle East and Africa
- Company Profiles
13.1 ADC Therapeutics SA
13.1.1 Quick Facts
13.1.2 Company Overview
13.1.3 Product Portfolio
13.1.4 Business Strategies
13.2 Amgen Inc.
13.2.1 Quick Facts
13.2.2 Company Overview
13.2.3 Product Portfolio
13.2.4 Business Strategies
13.3 AstraZeneca plc
13.3.1 Quick Facts
13.3.2 Company Overview
13.3.3 Product Portfolio
13.3.4 Business Strategies
13.4 Autolus Therapeutics plc
13.4.1 Quick Facts
13.4.2 Company Overview
13.4.3 Product Portfolio
13.4.4 Business Strategies
13.5 Bayer AG
13.5.1 Quick Facts
13.5.2 Company Overview
13.5.3 Product Portfolio
13.5.4 Business Strategies
13.6 BeOne Medicines GmbH
13.6.1 Quick Facts
13.6.2 Company Overview
13.6.3 Product Portfolio
13.6.4 Business Strategies
13.7 Eli Lilly and Company
13.7.1 Quick Facts
13.7.2 Company Overview
13.7.3 Product Portfolio
13.7.4 Business Strategies
13.8 Genmab A/S
13.8.1 Quick Facts
13.8.2 Company Overview
13.8.3 Product Portfolio
13.8.4 Business Strategies
13.9 Incyte Corporation
13.9.1 Quick Facts
13.9.2 Company Overview
13.9.3 Product Portfolio
13.9.4 Business Strategies
13.10 Ipsen
13.10.1 Quick Facts
13.10.2 Company Overview
13.10.3 Product Portfolio
13.10.4 Business Strategies
13.11 Jazz Pharmaceuticals
13.11.1 Quick Facts
13.11.2 Company Overview
13.11.3 Product Portfolio
13.11.4 Business Strategies
13.12 Johnson & Johnson
13.12.1 Quick Facts
13.12.2 Company Overview
13.12.4 Business Strategies
13.13 Kyowa Kirin Co., Ltd.
13.13.1 Quick Facts
13.13.2 Company Overview
13.13.3 Product Portfolio
13.13.4 Business Strategies
13.14 Merck & Co., Inc.
13.14.1 Quick Facts
13.14.2 Company Overview
13.14.3 Product Portfolio
13.14.4 Business Strategies
13.15 Pfizer Inc.
13.15.1 Quick Facts
13.15.2 Company Overview
13.15.3 Product Portfolio
13.15.4 Business Strategies
13.16 Regeneron Pharmaceuticals
13.16.1 Quick Facts
13.16.2 Company Overview
13.16.3 Product Portfolio
13.16.4 Business Strategies
13.17 Sanofi S.A.
13.17.1 Quick Facts
13.17.2 Company Overview
13.17.3 Product Portfolio
13.17.4 Business Strategies
13.18 Servier Pharmaceuticals
13.18.1 Quick Facts
13.18.2 Company Overview
13.18.3 Product Portfolio
13.18.4 Business Strategies
13.19 Takeda Pharmaceutical Company Limited
13.19.1 Quick Facts
13.19.2 Company Overview
13.19.3 Product Portfolio
13.19.4 Business Strategies
13.20 TG Therapeutics, Inc.
13.20.1 Quick Facts
13.20.2 Company Overview
13.20.3 Product Portfolio
13.20.4 Business Strategies
1. Global Lymphoma Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)
2. Global Chemotherapy Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Immunotherapy Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Targeted Therapy Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Radiation Therapy Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Stem Cell Transplantation Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global CAR-T Cell Therapy Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Lymphoma Treatment Market Research and Analysis by Lymphoma Type, 2025–2035 ($ Million)
9. Global Hodgkin Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Lymphoma Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
12. Global Intravenous (IV) Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Oral Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Subcutaneous Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Lymphoma Treatment for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Lymphoma Treatment for Speciality Cancer Centres Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Lymphoma Treatment for Ambulatory Surgical Centres Market Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Lymphoma Treatment for Research Institutes Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Global Lymphoma Treatment Market by Region, 2025–2035 ($ Million)
20. North America Lymphoma Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
21. Europe Lymphoma Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
22. Asia-Pacific Lymphoma Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
23. Rest of the World Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
1. Global Lymphoma Treatment Market Share by Segment, 2025 Vs 2035 (%)
2. Global Chemotherapy Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
3. Global Immunotherapy Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
4. Global Targeted Therapy Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
5. Global Radiation Therapy Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
6. Global Stem Cell Transplantation Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
7. Global CAR-T Cell Therapy Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
8. Global Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
9. United States Lymphoma Treatment Market Size, 2025-2035 ($ Million)
10. Canada Lymphoma Treatment Market Size, 2025-2035 ($ Million)
11. UK Lymphoma Treatment Market Size, 2025-2035 ($ Million)
12. France Lymphoma Treatment Market Size, 2025-2035 ($ Million)
13. Germany Lymphoma Treatment Market Size, 2025-2035 ($ Million)
14. Italy Lymphoma Treatment Market Size, 2025-2035 ($ Million)
15. Spain Lymphoma Treatment Market Size, 2025-2035 ($ Million)
16. Russia Lymphoma Treatment Market Size, 2025-2035 ($ Million)
17. India Lymphoma Treatment Market Size, 2025-2035 ($ Million)
18. China Lymphoma Treatment Market Size, 2025-2035 ($ Million)
19. Japan Lymphoma Treatment Market Size, 2025-2035 ($ Million)
20. South Korea Lymphoma Treatment Market Size, 2025-2035 ($ Million)
21. Australia & New Zealand Lymphoma Treatment Market Size, 2025-2035 ($ Million)
22. ASEAN Lymphoma Treatment Market Size, 2025-2035 ($ Million)
23. Rest of Asia-Pacific Lymphoma Treatment Market Size, 2025-2035 ($ Million)
24. Latin America Lymphoma Treatment Market Size, 2025-2035 ($ Million)
25. Middle East & Africa Lymphoma Treatment Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
